Sarcoidosis of skin
Methodology & AI Transparency ⓘ
Sarcoidosis of skin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as D86.3, Sarcoidosis of skin falls under Autoimmune Disease management, where early treat-to-target disease-modifying in Sarcoidosis of skin (D86.3: antirheumatic (DMARD/biologic) therapy) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Sarcoidosis of skin uses ICD-10 D86.3 across Autoimmune Disease specialty care.
- 3 Typical cash cost range: Differential triage of Sarcoidosis of skin (D86.3) utilizes early treat-to-target disease-modifying in Sarcoidosis of skin (D86.3: antirheumatic (DMARD/biologic) therapy).
- 4 Top reported side effects / signs: Longitudinal Sarcoidosis of skin monitoring tracks CBC, ALT & in Sarcoidosis of skin (D86.3: Creatinine (DMARD safety)) toward Within normal safety monitoring limits (D86.3).
Ask our AI Specialists anything about Sarcoidosis of skin
What Is Sarcoidosis of skin?
Designated in federal medical registries as D86.3, Sarcoidosis of skin falls under Autoimmune Disease management, where early treat-to-target disease-modifying in Sarcoidosis of skin (D86.3: antirheumatic (DMARD/biologic) therapy) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
In Sarcoidosis of skin (D86.3), physiological disruption stems from vascular inflammation [Sarcoidosis of skin D86.3], informing Rheumatoid Arthritis, Lupus & Autoimmune protocols that track hs-CRP & ESR [Sarcoidosis of skin D86.3] (hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (D86.3)).
Common Symptoms & Clinical Signs
- • Presentation of Sarcoidosis of skin (D86.3): triphasic Raynaud color in Sarcoidosis of skin (D86.3: changes in fingers)
- • Secondary Sarcoidosis of skin clinical sign: prolonged morning joint in Sarcoidosis of skin (D86.3: stiffness lasting over)
- • Symptom flares in Sarcoidosis of skin correlating with CBC, ALT & in Sarcoidosis of skin (D86.3: Creatinine (DMARD safety)) deviation outside Within normal safety monitoring limits (D86.3)
- • Functional autoimmune disease impact requiring early treat-to-target disease-modifying in Sarcoidosis of skin (D86.3: antirheumatic (DMARD/biologic) therapy) evaluation (D86.3)
Sarcoidosis of skin Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D86.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Rheumatoid Arthritis, Lupus & Autoimmune | NLM Clinical Tables |
| Diagnostic / Lab Marker: CBC, ALT & in Sarcoidosis of skin (D86.3: Creatinine (DMARD safety)) | Within normal safety monitoring limits (D86.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & ESR [Sarcoidosis of skin D86.3] | hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (D86.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ANA, RF, Anti-CCP in Sarcoidosis of skin (D86.3: & Complement C3/C4) | Disease-activity remission targets (D86.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sarcoidosis of skin
Treatment selection for Sarcoidosis of skin depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sarcoidosis of skin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the Although the JOQUER trial reported no overall benefit from HCQ in pSS patients, stratification suggests that. Rheumatology international • 2021-09-15 • Phase III Randomized Trial | N = 32 | 88/100 | PMID 34165604 ↗ |
| Can This Approach Help? Inside the Latest Research on A voclosporin-based triple immunosuppressive therapy to high-dose Compared with the high-dose GC-based regimens used in ALMS, voclosporin-based triple immunosuppressive therapy resulted in fewer AEs overall and greater and earlier reductions in proteinuria over the first 6 months of treatment. Lupus science & medicine • 2024-11-09 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39521453 ↗ |
Sarcoidosis of skin Patient Community & “People Like Me” Threads
Filter Sarcoidosis of skin community threads and patient logs by age, biological sex, dosage, and treatment duration.